pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

HELUS Pharma

updated 15d ago
Website ↗
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 1Phase 3: 1
1Phase 21Phase 3
Phase 3
deupsilocin besylate
Major Depressive Disorder
Phase 2
HLP-004
Generalized Anxiety Disorder (GAD)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view HELUS Pharma jobs →

News

  • Chutes & Ladders—BioNTech brings in Sobi CEO
    After a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the…
    fiercebiotech · 8d ago
  • J&J pharma leader to retire; Krystal slumps on gene therapy miss
    Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
    biopharma_dive · 10d ago
  • ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
    After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
    fiercebiotech · 27d ago
  • Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months
    → Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to CEO Albert Bourla. BMO Capital Markets broke the new…
    endpoints · 3mo ago
identifiers
source
globaldata
top tags
Major Depression1
mentioned in
4news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?